Cancer Diagnostics Market worth $44.92 billion by 2031
The report "Cancer Diagnostics Market by Product (Consumables (Antibodies, Probes), Instruments), Technology (IVD Testing, Anatomic pathology, Imaging, Biopsy), Type (Tumors, Breast, Lung Cancer), Application, End User (Hospitals) & Region – Global Forecast to 2031", is projected to grow from USD 29.86 billion in 2026 and to reach USD 44.92 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period.
Browse 250 market data Tables and 150 Figures spread through 300 Pages and in-depth TOC on "Cancer Diagnostics Market by Product (Consumables (Antibodies, Probes), Instruments), Technology (IVD Testing, Anatomic pathology, Imaging, Biopsy), Type (Tumors, Breast, Lung Cancer), Application, End User (Hospitals) & Region – Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/cancer-diagnostics-market-186559121.html
The rising global burden of cancer and the increasing emphasis on early disease detection are playing a crucial role in driving the cancer diagnostics market. Growing incidences of breast, lung, colorectal, prostate, and other cancers are fueling demand for accurate and timely diagnostic solutions across healthcare settings. Cancer diagnostic technologies, including imaging systems, biopsy techniques, molecular diagnostics, next-generation sequencing (NGS), immunohistochemistry, liquid biopsy, and biomarker-based tests, enable early detection, precise disease characterization, treatment selection, and continuous monitoring of disease progression. The increasing adoption of personalized medicine, supported by advancements in genomics, artificial intelligence, and digital pathology, is further accelerating market growth. Additionally, rising government initiatives for cancer screening, increasing healthcare investments, expanding access to advanced diagnostic services, and continuous innovations in non-invasive and minimally invasive diagnostic technologies continue to strengthen demand for cancer diagnostics solutions globally.
“Growing Demand for Automated Cancer Diagnostic Platforms Drives IVD Testing Instruments Segment.”
The IVD testing instruments segment dominated the cancer diagnostics market in 2025. The segment's dominance is primarily driven by the increasing global cancer burden and the growing demand for accurate, rapid, and high-throughput diagnostic testing across hospitals, diagnostic laboratories, cancer centers, and research institutions. The rising adoption of automated molecular diagnostic systems, immunoassay analyzers, clinical chemistry analyzers, flow cytometers, PCR platforms, next-generation sequencing (NGS) instruments, and digital pathology systems supports early cancer detection, biomarker analysis, companion diagnostics, and treatment monitoring. Continuous advancements in diagnostic technologies, including AI-assisted image analysis, laboratory automation, multiplex testing, and integrated data management systems, are improving diagnostic accuracy, laboratory efficiency, and clinical decision-making. In addition, increasing investments in oncology research, expanding cancer screening programs, growing adoption of precision medicine, favorable reimbursement policies in developed markets, and the continuous introduction of innovative diagnostic platforms continue to strengthen the segment's leading position, enabling IVD testing instruments to account for the largest market share among product categories in the cancer diagnostics market in 2025.
“Clinical Laboratories Lead the Cancer Diagnostics Market Through High-Volume Testing and Advanced Oncology Diagnostic Capabilities.”
The dominance of clinical laboratories in the cancer diagnostics market is driven by their central role in delivering high-volume, accurate, and comprehensive diagnostic testing for cancer detection, screening, prognosis, and treatment monitoring. Clinical laboratories are the primary end users of cancer diagnostic technologies, performing a wide range of molecular diagnostics, immunoassays, histopathology, cytogenetics, and biomarker testing to support precision oncology. The rising global burden of cancer, increasing adoption of early cancer screening programs, growing demand for personalized medicine, and expanding utilization of companion diagnostics continue to strengthen market growth. Furthermore, advancements in next-generation sequencing (NGS), liquid biopsy, digital pathology, and laboratory automation have significantly improved diagnostic accuracy, workflow efficiency, and turnaround times. Increasing investments in laboratory infrastructure, greater integration of artificial intelligence and digital data management systems and expanding access to advanced oncology testing further reinforce the leading position of clinical laboratories, enabling them to maintain the largest share of the global cancer diagnostics market.
“Asia Pacific Set to Witness Robust Growth in Point-of-Care Diagnostics Through 2031.”
Asia Pacific is projected to register the highest growth in the global cancer diagnostics market during the forecast period. Growth is driven by the region's large and aging population, rising incidence of cancer, increasing awareness of early cancer detection, and growing demand for accurate and timely diagnostic testing. Additionally, improving healthcare infrastructure, rising healthcare expenditure, supportive government-led cancer screening initiatives, and expanding access to advanced diagnostic services are accelerating market growth. The increasing adoption of molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, companion diagnostics, and digital pathology across hospitals and clinical laboratories is further enhancing diagnostic capabilities. Moreover, ongoing investments in precision oncology, expansion of specialized cancer care centers, and greater availability of innovative diagnostic technologies are expected to further strengthen the cancer diagnostics market across the Asia Pacific region.
Key Market Players:
Key players in this market are adopting various organic and inorganic growth strategies, including product launches, agreements, collaborations, acquisitions, and expansions Prominent players in the global point-of-care diagnostics market include Prominent players in the global cancer diagnostics market include Roche Diagnostics (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Exact Sciences Corporation (US), Guardant Health, Inc. (US), Sysmex Corporation (Japan), Foundation Medicine, Inc. (US), Myriad Genetics, Inc. (US), NeoGenomics Laboratories, Inc. (US), bioMérieux SA (France), and Revvity, Inc. (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cancer Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
